Partnership to promote the Biopharmaceutics Classification System
In a recent press release, Absorption Systems have announced a new partnership with Synerzys.
The US-based Absorption Systems, a preclinical CRO specializing in PK studies of new drug entities, and Synerzys, an Indian pharmaceutical consulting firm, are to collaborate in ordeer to internationally promote both the Biopharmaceutics Classification System (BCS) and Absorption Systems’ preclinical services.
The BCS is a regulatory pathway that classifies potential drug candidates, in terms of PK data, to provide further evidence to support further clinical testing of the therapeutic. Advocates of the system state that the system can be time- and cost-effective, and of particular use for generics.
President and Chief Executive Officer of Absorption Systems, Patrick Dentinger, discussed the system further, “The growing acceptance of the BCS has created the need for a more strategic view of India. In the low-margin, first-to-file world of generic drug products, companies will either use the BCS approach or compete with it.”
Chief Operating Officer of Synerzys, Kaushal Shah, explained that the company is happy to partner with Absorption Systems, “in an endeavour that has the potential for mutual commercial success as well as real benefits to patients in many countries.”
